LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence company focused on emerging markets, announced it has initiated an evaluation process to potentially integrate installment-based healthcare payments through Cashea, a leading buy-now-pay-later platform in Venezuela. The initiative aims to reduce financial barriers for patients seeking private healthcare services, including consultations, diagnostics, and wellness programs, via the LataMed AI ecosystem.
Management believes that improving payment accessibility could enhance patient engagement, increase healthcare utilization, and drive platform adoption. By addressing affordability challenges, the company hopes to strengthen its position as a technology-enabled healthcare marketplace serving patients, providers, and partners throughout Latin America. The potential integration aligns with LataMed AI's broader strategy of combining artificial intelligence, telehealth infrastructure, care coordination tools, and digital payment solutions to create a scalable healthcare marketplace.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, 'We believe financial accessibility is a critical component of healthcare delivery. Our objective is to evaluate solutions that may help patients obtain timely medical care while expanding the reach of our healthcare ecosystem. We believe initiatives such as this have the potential to strengthen patient acquisition, improve engagement, and support long-term platform growth.'
As of the release date, the company has not entered into a definitive commercial agreement. Completion of any integration remains subject to further discussions, technical requirements, regulatory review, and customary conditions. LataMed AI intends to provide updates as material developments occur. For more information, visit https://latamed.ai and review the company's SEC filings at www.sec.gov.
The news highlights a strategic move to leverage fintech partnerships to overcome economic barriers in healthcare access, potentially setting a precedent for similar integrations in other emerging markets. This development could significantly impact patient affordability and platform growth if successfully executed.
